Connection
Debopam Samanta to Cannabidiol
This is a "connection" page, showing publications Debopam Samanta has written about Cannabidiol.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
4.043 |
|
|
|
-
Samanta D. Pharmacotherapeutic management of seizures in patients with Angleman Syndrome. Expert Opin Pharmacother. 2022 Sep; 23(13):1511-1522.
Score: 0.737
-
Samanta D. Reply to comments on "A scoping review on cannabidiol therapy in tuberous sclerosis: Current evidence and perspectives for future development". Epilepsy Behav. 2022 06; 131(Pt A):108704.
Score: 0.725
-
Samanta D. A scoping review on cannabidiol therapy in tuberous sclerosis: Current evidence and perspectives for future development. Epilepsy Behav. 2022 03; 128:108577.
Score: 0.714
-
Samanta D. Changing Landscape of Dravet Syndrome Management: An Overview. Neuropediatrics. 2020 04; 51(2):135-145.
Score: 0.623
-
Samanta D. Cannabidiol: A Review of Clinical Efficacy and Safety in Epilepsy. Pediatr Neurol. 2019 07; 96:24-29.
Score: 0.585
-
van Eeghen AM, Thiele EA, Amin S, Samanta D, Jansen AC, Stevens J, Moore-Ramdin L, de Vries PJ. Protocol for EpiCom: A phase 3b/4 study of behavioral outcomes following adjunctive cannabidiol for the management of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND). PLoS One. 2025; 20(6):e0324648.
Score: 0.225
-
Samanta D. A comprehensive review of evolving treatment strategies for Dravet syndrome: Insights from randomized trials, meta-analyses, real-world evidence, and emerging therapeutic approaches. Epilepsy Behav. 2025 Jan; 162:110171.
Score: 0.217
-
Samanta D. Evolving treatment strategies for early-life seizures in Tuberous Sclerosis Complex: A review and treatment algorithm. Epilepsy Behav. 2024 Dec; 161:110123.
Score: 0.216